|
|
|
| The Analysis of SNP within GPR26 Gene and Tumor-Associated Latent Loci |
| WU Bin1, QU Fang1, CAO Peng-rong2, HU Jing1, YI Yin-sha1, ZHA Wen-ting1, LV Yuan1 |
1. Medical College of Hunan Normal University, Hunan Province Changsha 410006, China;
2. Changsha Yingrun Biotechnology Inc., Hunan Province Changsha 410013, China |
|
|
|
|
Abstract This study aims to investigate the association of SNPs with tumor-associated latent loci. By analyzing the effect of gene mutations on the structure and function of proteins with the database, to speculate the destructive mutants. It was found that individuals with the genotype of the five key SNP loci were more susceptible to tumors; these specific markers can be used as a molecular marker to determine the susceptibility of a tumor to the individual, and to diagnose the population with high risk of tumor; and rs201154887 can be used as a new disease molecular marker.
|
|
Received: 20 March 2017
|
|
|
| Fund:Graduate Student Research and Innovation Project of Hunan Province; grant number: CX2015B182;Educational Reform Project of Hunan Provincial Department of Education |
|
Corresponding Authors:
ZHA Wen-ting， Lv Yuan. E-mail: 183259829@qq.com, ly598598@126.com
|
|
|
|
[1] Fang KH, Chang XT. Advances in single nucleotide polymorphism and tumor genetic susceptibility[J]. Chinese
Journal of Cancer Prevention and Treatment, 2011,18(2):151-155.
[2] Chitranshi N, Dheer Y, Wall RV, et al. Computational analysis unravels novel destructive single nucleotide polymorphisms in the non-synonymous region of human caveolin gene[J]. Gene Reports, 2017, 6: 142-157.
[3] Shridhar K, Aggarwal A, Walia GK, et al. Single nucleotide polymorphisms as markers of genetic susceptibility for oral potentially malignant disorders risk: Review of evidence to date[J]. Oral Oncology, 2016, 61: 146-151.
[4] Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily[J]. Annual Review of Pharmacology Toxicology, 2013,53:531-556.
[5] Ward R, Milligan JG. Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques[J]. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2014,1838(1, Part A): 3-14.
[6] Montaner S, Kufareva I, Abagyan R, et al. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases[J]. Annual Review of Pharmacology Toxicology, 2013,53:331-354.
[7] Mallipeddi S, Janero DR, Zvonok N, et al. Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets[J]. Biochemical Pharmacology, 2017, 128: 1-11.
[8] Boulay JL, Ionescu MC, Sivasankaran B. The 10q25.3-26.1 G protein-coupled receptor gene GPR26 is epigenetically silenced in human gliomas[J].International Journal of Oncology, 2009, 35(5):1123-1131.
[9] Zhang LL, Wang JJ, Liu Y, et al. GPR26-deficient mice display increased anxiety-and depression-like behaviors accompanied by reduced phosphorylated cyclic AMP responsive element-binding protein level in central amygdala[J]. Neuroscience,2011, 196:203-214.
[10] Ynang J, Gao W, Gu XX, et al. Clustering analysis of biological sequences [J]. Bioinformatics,2009,7(1):64-67.
[11] Gu SQ, Zhang YF, Fan YS, et al. Homology analysis of MAPK protein in biological database[J]. Journal of Agricultural University of Hebei, 2010,33(4):58-66.
[12] Duan JB, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor[J]. Human Molecular Genetics, 2003,12:205-216.
[13] Evans WE, Mcleod HL. Pharmacogenomics - drug disposition, drug targets, and side effects[J]. The New England Journal of Medicine, 2003, 348:538-546. |
|
|
|
